Brief: Innoviva Announces FDA Acceptance And Priority Review Of New Drug Application For Sulbactam-Durlobactam
30/11/2022 21:59
Nov 30 (Reuters) - Innoviva Inc INVA.O :
* INNOVIVA ANNOUNCES FDA ACCEPTANCE AND PRIORITY REVIEW OF
NEW
DRUG APPLICATION FOR SULBACTAM-DURLOBACTAM (SUL-DUR)
* TARGET PDUFA DATE IS MAY 29, 2023
Source text for Eikon: ID:nBw8krlsva
Further company coverage: INVA.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Innoviva
See all newsInnoviva, Inc. reports results for the quarter ended June 30 - Earnings Summary
Innoviva Q2 revenue rises on higher net product sales
Brief: Innoviva Q2 Royalty Revenue USD 56.334 Million
Brief: Nortiva Bio Launches To Develop Long-Acting Oral Medicines
Brief: Innoviva Q1 Royalty Revenue USD 55.167 Million